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ABSTRACT 
In the vast majority of human populations, the gene encoding CASPASE-12 (CASP12) has a 
premature termination codon that precludes the production of protein.  However, approximately 
20% of persons of recent African descent have a single nucleotide polymorphism (#rs497116; 
A->G) that turns the stop codon into one encoding Arg.  The subsequent functional allele is a 
risk factor for sepsis as it uniquely downregulates inflammatory cytokines in African-Americans 
(AA).  To determine if CASP12 could be protective for systemic lupus erythematosus (SLE) in 
AA, we genotyped AA SLE patients and controls. There was a weak association between 
CASP12 genotype with the absence of anti-dsDNA autoantibodies in SLE patients.  No effect 
was seen upon serum interleukin-1 beta levels, nor was any other protective effect noted for the 
CASP12 genotype, whether upon association with SLE, or any of the 11 American College of 
Rheumatology classification criteria.  CASP12 genotype thus does not influence the phenotype 
of SLE in AA. 
 
1. Introduction 
 In mice, CASPASE-12 (CASP12) modulates both the inflammatory process and the 
cellular apoptotic pathway.     A truncated pseudogene (CASP12p1) resulting from a premature 
termination mutation is found in all Caucasians and East Asians examined, and in 80% of 
people of African lineage [1].  Thus, while most humans lack a functional CASP12 gene, 
approximately 20% of persons of African descent have a functional pseudogene that is rescued 
by a single nucleotide polymorphism (#rs497116; A->G) that turns the premature stop codon 
into one encoding Arg [2,3].  The functional allele is a risk factor for sepsis in persons of African 
descent due to its genotype-dependent ability block inflammasome and CASP1 activation [4,5] 
which in turn down-regulates inflammatory cytokines such as interleukin-1β (IL1 β) in responses 
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to pro-inflammatory mediators such as bacterial lipopolysaccharide [1].  In addition, knockout 
mice lacking CASP12 are less susceptible to sepsis and death than wild-type mice [5].   
 A corollary to the observation that CASP12 is a risk factor for sepsis would be that 
CASP12 is protective against some inflammatory autoimmune diseases, particularly systemic 
lupus erythematosus (SLE), in AA populations.  SLE is a serious inflammatory disease with 
protean manifestations that can affect any organ system.  The diverse nature of SLE requires 
classification by the presence of no less than 4 of 11 criteria, as defined by the American 
College of Rheumatology [6,7].  Gender, environment, and genetic factors influence the 
development of SLE [8,9], with over 40 genes known to play a role in SLE pathogenesis [10]. A 
number of these genes are specific SLE risk factors in AA individuals [9]. 
 AA have the highest prevalence of SLE among all ethnic groups, regardless of age, 
gender, or socio-economic class. They manifest the disease with greater severity and burden, 
and have worse prognoses and higher mortality rates [8,11,12].  AA patients tend to have more 
frequent organ system involvement, higher auto-antibody titers, and a more pronounced 
pathological course.  Clinically, these patients develop organ-specific damage at a faster rate 
than white SLE patients [13], and are more likely to have severe disease flares [14]. We thus 
chose to assess the role of CASP12 in SLE using AAs selected from the Lupus Family Registry 
and Repository cohort [15].    
2. Material and methods  
2.1 Study population 
The Lupus Family Registry and Repository (LFRR) is a large, multi-ethnic cohort of SLE-
affected individuals, their unaffected family members, and healthy population-based controls 
supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases [15]. Our 
study group included 714 AA SLE patients and 325 healthy, population-based AA controls 
(demographics provided in Table 1).  Study subjects were self-defined African Americans who 
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satisfied at least 4 of the 11 criteria for the classification of SLE [6,7]. Sera were stored at -80o C 
until use.  
 
2.2 DNA genotyping  
CASP12  genotyping was performed in a single tube assay [16] by allele-specific polymerase 
chain reaction (PCR) using primers containing a mismatch introduced at the second base from 
the 3’ end to improve allele specificity [17] .  Primers were C12-P1 
(GAGTCACTATCGAGGAAGTCTCCATG), C12-P2X (TTCTGAACTTGACCTTTTGGGGATTC), 
C12-P3X (TATCCAAGGTTTTCAAGTAGATCTAA), and P12-P4 
(CTTCACATTACATTTTCTGTTTCTTCCATC).  PCR parameters were an initial 60 sec of 
denaturation at 94o C, 5 sec of priming at 55o C, and 5 sec of extension at 72o C, for 30 cycles, 
using SpeedSTAR HS or Sapphire DNA polymerase (Takara, Madison, WI).  PCR products 
were analyzed on a 1% agarose gel.  To verify results, the polymorphic portion of CASP12 was 
subjected to DNA sequencing using a high-fidelity DNA polymerase.  Sequence analysis was 
sensitive enough to discriminate between homozygous and heterozygous individuals. 
2.3 ELISA analysis 
Serum interleukin-1β (IL-1β) levels were measured using a Biolegend (San Diego, CA) ELISA-
MAX Deluxe ELISA kit according to the manufacturer’s instructions. 
 
2.4 Statistical Analyses 
Pearson’s chi square statistics or Fisher’s exact p values (not adjusted for multiple testing) were 
generated for full model genetic analyses of CASP12 using the PLINK software program [18].  
Cytokine analyses included non-parametric 2-tailed t tests with Mann-Whitney corrections.  P < 
0.05 was considered statistically significant.  
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3. Results 
3.1 CASP12 has no overall effect on SLE in AAs 
 To determine if CASP12 is protective against SLE in AAs due to its anti-inflammatory 
functions, we genotyped the CASP12 SNP rs497116 in a total of 714 AA patients and 325 AA 
controls (all unrelated). Eight SLE patients (1.1%) were homozygous C12, 152 (21.3%) were 
heterozygous p1/C12, and 554 (77.6%) were homozygous p1 (Table 2).  These frequencies 
were similar to our normal control group and to normal controls reported in other studies [1,3]. 
Allele frequencies were comparable:  88% for p1 and 12% for C12 alleles in cases; 87% for the 
p1 allele and 13% for the C12 allele in controls. There was no association with CASP12 
genotype and any of the 11 ACR classification criteria for SLE (Table 2) in case-control 
analyses, nor was there any effect by CASP12 upon clinical criteria within patients in a case-
only design, i.e., having or lacking CASP12 did not affect a patient from being susceptible to, or 
protected from any particular clinical presentation (Table 3). 
The LFRR did not calculate Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) scores for their patient population. We therefore, approximated the severity of their 
disease at time of enrollment by defining “severe” manifestations of SLE as any case having 
renal disease, plus neurological manifestations or serositis.  Using these criteria, we did not 
observe any association between CASP12 genotype and the more pathological presentations of 
SLE.  Therefore, when evaluating SLE as a phenotype, there was no significant association 
observed with CASP12.  
 
3.2 CASP12 does not affect serum IL-1β levels in AAs with SLE   
 With the data suggesting that CASP12 plays a protective role in one aspect of SLE, we 
sought to determine if the mechanism involved would be mediated by IL-1β, the cytokine best 
known to be influenced by CASP12 [1,5].  IL-1β production by peripheral blood mononuclear 
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cells (PBMCs) is reduced in lupus patients compared to normal controls [19], while serum IL-1β 
levels are elevated [20].  Our hypothesis was that IL-1β would be substantially reduced in a 
genotype-dependent manner.  In testing 29 subjects (15 patients and 14 controls), there was no 
significant difference in IL-1β levels between patients and controls when evaluated by CASP12 
genotype (Fig.1a), nor was there any difference amongst individuals, when grouped by 
genotype only (Fig 1b).  
   
3.3 CASP12 protects against dsDNA antibodies of SLE in AAs.   
 The effect of the CASP12 genotype was also assessed for six different autoantibodies in 
a case-only analysis (anti-dsDNA, -Sm, -Ro, -La, -snRNP, and -cardiolipin). Of the patients for 
whom we have autoantibody data, a weak but significant effect was only observed for anti-
dsDNA, either with a genotypic (p=0.045) or allelic (p=0.032) model (Table S1).   
 
4. Discussion 
 We have found that CASP12 genotype is neither a risk factor nor protective against SLE 
in African-Americans.  CASP12 polymorphisms do not affect any of the 11 ACR classification 
criteria, but have, at best, a weak protective effect against the development of at least one 
autoantibody.  
While our data do not demonstrate the CASP12 genotype had a significant effect upon 
serum levels of IL-1β or any symptomology of SLE, we recognize that we evaluated a small 
sample.  Indeed, we observe that the cases homozygous for the CASP12p1 allele have no IL-
1β in their serum while three of the four controls that we evaluated have between 100-400 
pg/ml. As relatively low numbers of African-Americans carry both copies of CASP12 (about 1-
3% of the population [1, 3 and our data], for the number of cases evaluated, changes in even 
small numbers could affect the significance of the results, and therefore, replication studies 
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should be performed before a strong conclusion can be drawn about CASP12 genotype and 
SLE, especially concerning the role of IL-1β in lupus. 
Close to 200 autoantibodies have been identified in SLE patients [21].  Such 
autoantibodies often function as biomarkers for disease activity, have pathogenic roles, and/or 
are part of diagnostic criteria [22-24].  Given the importance of their role in SLE, we tested 
whether CASP12 genotype would affect the presence or absence for six different 
autoantibodies (anti-dsDNA, -Sm, -Ro, -La, -snRNP, and -cardiolipin).  We observed, at best, a 
weak but significant effect for anti-dsDNA.  Yet after adjusting for multiple testing in the case-
control and case-case analyses, no significant results remained, and no significant effects were 
seen for the other autoantibodies. 
 In addition to CASP12, in humans the inflammatory caspase family includes CASP1 (the 
best studied) [25], CASP4 and CASP5.  CASP1 triggers inflammation and mediates 
inflammatory cell death by pyroptosis via the activation of IL-1β and IL18 from inactive pro-
hormones receptors [26].  Activation of CASP1 requires assembly and activation the 
inflammasome complex following danger signals transmitted from pattern recognition [27].  
CASP4 and 5 are also part of the inflammasome and activated by this complex [28]. 
What evidence is there for overt roles for the inflammatory caspases in the pathogenesis 
of autoimmunity?  Other than CASP1 contributing to murine lupus [29], very little is known about 
the role of CASP4 and 5 in the pathogenesis of autoimmunity [27] although data is emerging 
that the latter caspases are involved in autoimmune skin [30] and bowel diseases [31], along 
with SLE [32]. 
Given the reported downregulatory effects the protein exerts upon IL1 production via 
inhibition of CASP1 [1,5] it was surprising that that we observed so few effects.  We expected to 
see reduced serum IL-1β levels in our patient group, with the lowest levels in the CASP12 
homozygous patients, especially given that defects in the ability of PBMCs to produce IL-1β 
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occur in SLE patients [19] and decreased IL-1β levels in patient serum have been described 
[20].    This was not the case. It should be considered, however, that nearly all studies on IL-1β 
production in SLE patients involve groups such as Caucasians or Asians who carry the p1/p1 
genotype [33].  Therefore, CASP12’s effects may be qualitative at the cellular level rather than 
quantitative at the serologic level, and other inflammatory cytokines need to be examined.   
If CASP12 is indeed downregulatory, it may fail to reduce serum concentrations of IL-1β 
or other pathogenic cytokines below disease-inducing levels, but does so at the cellular level.  
This notion is supported by our observation that CASP12 genotype is not protective against the 
development of rheumatoid arthritis (RA) in AA, but is protective against RA radiologic 
abnormalities [34].  Surprisingly, obese African-American children had lower serum IL6 and C-
reactive protein levels, as well as less macrophage infiltration into adipose tissues,  if they were 
CASP12-positive [35]. 
The key question that emerges: is CASP12 actually anti-inflammatory?  Our own 
findings bring to mind “the dog that didn’t bark”.  CASP12 genotype does not influence 
susceptibility or adverse events in African-Americans or black South Africans with community-
acquired pneumonia [36].   In addition, susceptibility to Candida sepsis in Africans is not 
affected by CASP12 genotype, nor does it have any effect on serum cytokine concentrations in 
septic candidiasis patients [37] or in responses to Yersinia pestis [38].   CASP12’s effects upon 
TNF production, which is elevated in all lupus patients, especially AA [39], is also contradictory 
[38,40,41].  Further, while hepatitis C virus is a IL1 inducer [42], CASP12 genotype has no 
effect in the clearance of this pathogen [43].  Confounding the metabolic findings described 
above by Skeldon and co-workers, no protective effects were found in African-American adults 
with CASP12 when metabolic parameters or C-reactive protein levels were assessed [35].  
While these differences may be due to sample size, populations tested, underlying 
disease states assessed, or the assay systems used, one other observation is worth noting:  In 
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transgenic mice carrying human CASP12, the gene is downregulated in a gender-specific 
manner, due to an endogenous estrogen response element [41].  Yet there is a profound 
skewing of the gender ratio in SLE:  90% of AA SLE patients are female [44] while male lupus 
patients have a more severe phenotype and worse outcomes [45,46].  A protective CASP12 
gene product would be expect to yield the opposite ratios. 
The down-regulatory effects of CASP12 may be subtle enough that it can increase risk 
for bacterial sepsis, yet not interrupt the pathogenesis of autoimmunity.  It may be that in other 
autoimmune or autoinflammatory disorders that CASP12 has a protective role, but thus far, 
using CASP12 genotype to predict protection from, or disease outcomes in rheumatic diseases, 
appears to be problematic. 
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Figure Legends 
 
Fig 1.  CASP12 genotype has no effect upon serum levels of IL1β when comparing 
patients and controls.  p1/p1, CASP12p1 homozygous; C12/p1, CASP12p1/CASP12 
heterozygous; C12/C12, CASP12 homozygous.  Data represent means of two-well replicates 
assayed via ELISA.  Open circles, patients.  Closed circles, normal controls.   
 
 
 
 
 
